Comparison Overview

SpringWorks Therapeutics

VS

Gilead Sciences

SpringWorks Therapeutics

100 Washington Blvd, Stamford, Connecticut, 06902, US
Last Update: 2025-03-05 (UTC)
View Profile
Between 750 and 799
http://www.springworkstx.com

SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and delivering life-changing medicines for people with severe rare diseases and cancer. Founded in 2017, SpringWorks has a diversified targeted oncology pipeline spanning solid tumors and hematological cancers, including clinical trials in rare tumor types and highly prevalent, genetically defined cancers.

NAICS: 541714
NAICS Definition: Research and Development in Biotechnology (except Nanobiotechnology)
Employees: 388
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0
View Profile

Gilead Sciences

333 Lakeside Drive, Foster City, CA, US, 94404
Last Update: 2025-09-17 (UTC)
Between 750 and 799
http://www.gilead.com

At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine. Our focus goes beyond medicines, and we also strive to remedy health inequities and break down barriers to care. We empower our people to tackle these challenges, and we’re all united in our commitment to help millions of people live healthier lives. Social Media Guidelines: https://www.gilead.com/social-media-guidelines

NAICS: 541714
NAICS Definition: Research and Development in Biotechnology (except Nanobiotechnology)
Employees: 14,615
Subsidiaries: 10
12-month incidents
1
Known data breaches
1
Attack type number
2

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/springworks-therapeutics.jpeg
SpringWorks Therapeutics
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/gilead-sciences.jpeg
Gilead Sciences
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
SpringWorks Therapeutics
100%
Compliance Rate
0/4 Standards Verified
Gilead Sciences
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Biotechnology Research Industry Average (This Year)

No incidents recorded for SpringWorks Therapeutics in 2025.

Incidents vs Biotechnology Research Industry Average (This Year)

Gilead Sciences has 132.56% more incidents than the average of same-industry companies with at least one recorded incident.

Incident History — SpringWorks Therapeutics (X = Date, Y = Severity)

SpringWorks Therapeutics cyber incidents detection timeline including parent company and subsidiaries

Incident History — Gilead Sciences (X = Date, Y = Severity)

Gilead Sciences cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/springworks-therapeutics.jpeg
SpringWorks Therapeutics
Incidents

No Incident

https://images.rankiteo.com/companyimages/gilead-sciences.jpeg
Gilead Sciences
Incidents

Date Detected: 2/2025
Type:Breach
Attack Vector: Human Error (Mailing Error)
Blog: Blog

Date Detected: 05/2020
Type:Cyber Attack
Attack Vector: Phishing, Server Compromise
Blog: Blog

FAQ

Gilead Sciences company demonstrates a stronger AI Cybersecurity Score compared to SpringWorks Therapeutics company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Gilead Sciences company has historically faced a number of disclosed cyber incidents, whereas SpringWorks Therapeutics company has not reported any.

In the current year, Gilead Sciences company has reported more cyber incidents than SpringWorks Therapeutics company.

Neither Gilead Sciences company nor SpringWorks Therapeutics company has reported experiencing a ransomware attack publicly.

Gilead Sciences company has disclosed at least one data breach, while SpringWorks Therapeutics company has not reported such incidents publicly.

Gilead Sciences company has reported targeted cyberattacks, while SpringWorks Therapeutics company has not reported such incidents publicly.

Neither SpringWorks Therapeutics company nor Gilead Sciences company has reported experiencing or disclosing vulnerabilities publicly.

Neither SpringWorks Therapeutics nor Gilead Sciences holds any compliance certifications.

Neither company holds any compliance certifications.

Gilead Sciences company has more subsidiaries worldwide compared to SpringWorks Therapeutics company.

Gilead Sciences company employs more people globally than SpringWorks Therapeutics company, reflecting its scale as a Biotechnology Research.

Neither SpringWorks Therapeutics nor Gilead Sciences holds SOC 2 Type 1 certification.

Neither SpringWorks Therapeutics nor Gilead Sciences holds SOC 2 Type 2 certification.

Neither SpringWorks Therapeutics nor Gilead Sciences holds ISO 27001 certification.

Neither SpringWorks Therapeutics nor Gilead Sciences holds PCI DSS certification.

Neither SpringWorks Therapeutics nor Gilead Sciences holds HIPAA certification.

Neither SpringWorks Therapeutics nor Gilead Sciences holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

The Bold Page Builder plugin for WordPress is vulnerable to Stored Cross-Site Scripting via the ‘percentage’ parameter in all versions up to, and including, 5.4.5 due to insufficient input sanitization and output escaping. This makes it possible for authenticated attackers, with Contributor-level access and above, to inject arbitrary web scripts in pages that will execute whenever a user accesses an injected page.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 6.4
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:L/I:L/A:N
References
Description

The ComboServlet in Liferay Portal 7.4.0 through 7.4.3.111, and older unsupported versions, and Liferay DXP 2023.Q4.0 through 2023.Q4.2, 2023.Q3.1 through 2023.Q3.5, 7.4 GA through update 92, 7.3 GA through update 35, and older unsupported versions does not limit the number or size of the files it will combine, which allows remote attackers to create very large responses that lead to a denial of service attack via the URL query string.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary directories on the target machine.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and create arbitrary directories on the target machine.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary files on the target machine.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 7.5
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:H
cvss4
Base: 8.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:H/SC:N/SI:L/SA:L/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References